
Automated data analysis from review-by-exception to AI exploration

Tuesday, December 1 at 16:00 GMT | 17:00 CET | 11:00 EST | 08:00 PST
Robotic systems can generate experimental data at unprecedented speed, but analysis and review do not always keep pace. Closing this automation gap will be increasingly important as drug discovery teams move toward connected, closed-loop Design-Make-Test-Analyze workflows and faster, more adaptive decisions.
Michael Gallagher, Principal Scientist in Automation and Screening Operations at Johnson & Johnson Innovative Medicine, will draw on his experience spanning automated data generation, enterprise analytics, AI/ML frameworks, and predictive modeling. Moderated by Ada Yee of Genedata, the discussion will examine the progression from manual assessment toward review-by-exception and increasingly autonomous discovery workflows.
Using Genedata Screener as a practical example, the session will explore how automated quality control, validation, masking, and reporting can reduce routine review while keeping scientists focused on results that require expert attention. It will also consider the potential of AI agents to support result rescue and advance the journey toward closed-loop drug discovery.
Certificate of attendance
If you attend the live webinar, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.
Webinar details
- Cost: Free to attend
- Location: Online
- Duration: 60 minutes
Registration is required to secure your place. If you register but can’t attend live, you will receive a link to the on‑demand recording once it becomes available.
Speakers



Who should attend?
- R&D scientists: Explore how automated analysis and review-by-exception can streamline experimental data review.
- Automation scientists: See how automation can extend from laboratory processes into data analysis, QC, validation, and reporting.
- Bioinformaticians & Data scientists: Explore the role of automated data workflows and AI agents in data assessment and decision-making.
- IT & Digital transformation leaders: Gain insights into how increasingly automated and AI-driven data analysis can contribute to the transition toward closed-loop drug discovery workflows.
- R&D managers: Understand how automation can reduce data analysis bottlenecks and accelerate drug discovery workflows.
What will this webinar cover?
- The role of automated data analysis in enabling closed-loop drug discovery workflows.
- How review-by-exception workflows reduce manual review through automated QC, validation, and masking.
- Different levels of automation through Co-Scientist and Auto-Scientist workflows, from targeted expert review to automated processing and publication of results.
- The potential of AI agents to improve quality control, data validation, and result rescue within automated workflows.
